{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:57:25Z","timestamp":1754161045758,"version":"3.41.2"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,28]]},"DOI":"10.7759\/cureus.88898","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:32:08Z","timestamp":1753705928000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Metabolic Effects of Incretin-Based Pharmacotherapy in Normal-Weight Patients With Type 2 Diabetes: A Real-World Analysis"],"prefix":"10.7759","author":[{"given":"Erin","family":"Carson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Khaleq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassidy","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanis","family":"Rodriguez Colon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.10.027","article-title":"Minority representation in clinical trials in the United States: trends over the past 25 years","volume":"96","author":"Ma MA","year":"2021","unstructured":"Ma MA, Guti\u00e9rrez DE, Frausto JM, Al-Delaimy WK. Minority representation in clinical trials in the United States: trends over the past 25 years. Mayo Clin Proc. 2021, 96:264-6. 10.1016\/j.mayocp.2020.10.027","journal-title":"Mayo Clin Proc"},{"key":"ref2","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report website. (2024). Accessed. April 10, 2024: https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS- 1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock J","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al.. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS- 1): a double-blind, randomised, phase 3 trial. Lancet. 2021, 398:143-55. 10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS- 4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato S","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, et al.. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS- 4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021, 398:1811-24. 10.1016\/S0140-6736(21)02188-7","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli C","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, et al.. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017, 5:251-60. 10.1016\/S2213-8587(17)30013-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard HW","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J, et al.. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018, 103:2291-301. 10.1210\/jc.2018-00070","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre M","year":"2009","unstructured":"Marre M, Shaw J, Br\u00e4ndle M, et al.. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009, 26:268-78. 10.1111\/j.1464-5491.2009.02666.x","journal-title":"Diabet Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1625","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)","volume":"38","author":"Giorgino F","year":"2015","unstructured":"Giorgino F, Benroubi M, Sun JH, et al.. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015, 38:2241-9. 10.2337\/dc14-1625","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez G","year":"2014","unstructured":"Umpierrez G, Tof\u00e9 Povedano S, P\u00e9rez Manghi F, et al.. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014, 37:2168-76. 10.2337\/dc13-2759","journal-title":"Diabetes Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11)","volume":"44","author":"Frias JP","year":"2021","unstructured":"Frias JP, Bonora E, Nevarez Ruiz LA, et al.. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021, 44:765-73. 10.2337\/dc20-1473","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda VR","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, et al.. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019, 42:1724-32. 10.2337\/dc19-0749","journal-title":"Diabetes Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley RE","year":"2019","unstructured":"Pratley RE, Amod A, Hoff ST, et al.. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019, 394:39-50. 10.1016\/S0140-6736(19)31271-1","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022, 65:1925-66. 10.2337\/dci22-0034","journal-title":"Diabetologia"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002517","article-title":"Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK","volume":"10","author":"Weiss T","year":"2022","unstructured":"Weiss T, Yang L, Carr RD, et al.. Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. BMJ Open Diabetes Res Care. 2022, 10:e002517. 10.1136\/bmjdrc-2021-002517","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01337-5","article-title":"The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis","volume":"16","author":"Yugar LBT","year":"2024","unstructured":"Yugar LBT, Sedenho-Prado LG, da Silva Ferreira IMC, et al.. The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis. Diabetol Metab Syndr. 2024, 16:92. 10.1186\/s13098-024-01337-5","journal-title":"Diabetol Metab Syndr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13853","article-title":"Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index","volume":"21","author":"Gentilella R","year":"2019","unstructured":"Gentilella R, Sesti G, Vazquez L, et al.. Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index. Diabetes Obes Metab. 2019, 21:2660-6. 10.1111\/dom.13853","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200433","article-title":"Glycemia reduction in type 2 diabetes\u2014glycemic outcomes","volume":"387","author":"GRADE Study Research Group","year":"2022","unstructured":"GRADE Study Research Group, Nathan DM, Lachin JM, et al.. Glycemia reduction in type 2 diabetes\u2014glycemic outcomes. N Engl J Med. 2022, 387:1063-74. 10.1056\/NEJMoa2200433","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/385233-clinical-and-metabolic-effects-of-incretin-based-pharmacotherapy-in-normal-weight-patients-with-type-2-diabetes-a-real-world-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T12:32:09Z","timestamp":1753705929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/385233-clinical-and-metabolic-effects-of-incretin-based-pharmacotherapy-in-normal-weight-patients-with-type-2-diabetes-a-real-world-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.88898","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}